Form 8-K - Current report:
SEC Accession No. 0001104659-24-122387
Filing Date
2024-11-25
Accepted
2024-11-25 08:30:10
Documents
14
Period of Report
2024-11-21
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2429233d1_8k.htm   iXBRL 8-K 37711
2 EXHIBIT 99.1 tm2429233d1_ex99-1.htm EX-99.1 12889
  Complete submission text file 0001104659-24-122387.txt   229647

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ibio-20241121.xsd EX-101.SCH 3012
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ibio-20241121_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ibio-20241121_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2429233d1_8k_htm.xml XML 3681
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 241492084
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)